Toonasinetins A and B, two new compounds from the branches and leaves of Toona sinensis

IF 1.7 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-12-01 Epub Date: 2025-10-24 DOI:10.1016/j.phytol.2025.104065

Nai-Dong Li , Cheng-Shan Wei , Chun-Xia Song , Chun-Jiang Du , Juan Xu

引用次数: 0

Abstract

Two previously unreported aromatic natural products, toonasinetin A (1) and toonasinetin B (2), along with three known compounds (3–5), were isolated from the methanolic extracts of the branches and leaves of Toona sinensis. The chemical structures of compounds 1 and 2 were established by 1D, 2D NMR, HRESIMS, UV, IR analysis, and calculating electronic circular dichroism (ECD). The structures of known compounds 3–5 were determined by comparison of their spectral data with those reported in the literature. These findings expand the known phytochemical diversity of this species and contribute to its chemotaxonomic characterization.

查看原文本刊更多论文

香椿枝和叶中的两个新化合物香椿素A和B

从香椿枝和叶的甲醇提取物中分离出两种以前未报道的芳香天然产物，香椿素A(1)和香椿素B(2)，以及三种已知化合物（3-5）。通过1D、2D NMR、hresms、UV、IR分析和电子圆二色性（ECD）计算，确定了化合物1和2的化学结构。已知化合物3-5的结构是通过与文献报道的光谱数据比较确定的。这些发现扩大了该物种已知的植物化学多样性，并有助于其化学分类表征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.